Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Search
Martin Stefanic
Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Patient safety your career opportunity
Discover a role in Patient Safety
PRRS Research Award 2022
Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
Career tips from our Global Head of HR
Sven Sommerlatte explains how important it is to reflect on the personal career strategy.
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
10 tips cat friendly veterinary clinics
Here are 10 simple steps you can take to make feline patients feel at ease at your practice.
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Cooperation with The Defeat-NCD Partnership
Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Professor Baumgart
Information for people with type 2 diabetes (T2D) on why it is important to consider their heart and suggested measures that can be taken to reduce the risk of heart disease
Practical Advice
Practical advice for people with type 2 diabetes (T2D) at risk of heart disease
Streetvet: Free veterinary care
Learn more about StreetVet free veterinarian care for companion animals of the homeless
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
Awards & International Recognition| Bioxcellence | Boehringer Ingelheim
Explore Bioxcellence's global recognition, showcasing our prestigious awards & certifications. Witness our commitment to excellence in biopharmaceuticals!
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Cooperation with Google Quantum AI
Bowel Issues
Find out how to handle changes to bowel habits following cancer treatment from Taking Cancer On Through Flavour
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Partnering-with-google-in-quantum-computing
New cooperation with Google explores the potentials of quantum computing for pharma R&D.
Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.